Analyst Price Target is $5.00
▲ +75.44% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Liquidia in the last 3 months. The average price target is $5.00, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a 75.44% upside from the last price of $2.85.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Liquidia. This rating has held steady since February 2020, when it changed from a Hold consensus rating.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.